Stroke AHA/ASA/X
Jun 12, 2025, 06:59
DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy
Stroke AHA/ASA shared on X:
“STROKE In the Multicenter International Study ACTION CVT, patients with Cerebral Venous Thrombosis treated with DOACs had similar rate of thrombosis recurrence and recanalization rates, but lower risk of major hemorrhages, when compared to warfarin (1/3)”
Title: Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF.
Authors: Arnar B. Ingason, Brynja R. Gudmundsdottir, Ragnar Palsson, Johann P. Hreinsson, Sigrun H. Lund, Loic R. Letertre, Edward Rumba, Arnar S. Agustsson, Einar S. Bjornsson, Pall T. Onundarson.
Read more about it in Blood Vessels, Thrombosis & Hemostasis (2025).
Discover more in Hemostasis Today.
Arnar B. Ingason
Arnar S. Agustsson
ASH
Blood Vessels
Brynja R. Gudmundsdottir
BVTH 2025
Cerebral Venous Thrombosis
DOACs
DOACs vs. Warfarin
Edward Rumba
Einar S. Bjornsson
Johann P. Hreinsson
Loic R. Letertre
Pall T. Onundarson.
Ragnar Palsson
Sigrun H. Lund
Study ACTION CVT
Thrombosis & Hemostasis
Thrombosis and Haemostasis
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 05:33Women with Hemophilia Finally Heard: “DISMISSED” Premieres August 22
-
Aug 4, 2025, 04:58Women with Inherited Bleeding Disorders: Overcoming Diagnostic and Clinical Challenge
-
Aug 4, 2025, 01:37EAHAD Launches Italian Booklet to Support Young Girls With Bleeding Disorders During Their First Period
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
Aug 4, 2025, 05:33